Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Blood cancer journal (New York) 2021-02, Vol.11 (2), p.25-6, Article 25
Hauptverfasser:	Maiti, Abhishek, DiNardo, Courtney D., Daver, Naval G., Rausch, Caitlin R., Ravandi, Farhad, Kadia, Tapan M., Pemmaraju, Naveen, Borthakur, Gautam, Bose, Prithviraj, Issa, Ghayas C., Short, Nicholas J., Yilmaz, Musa, Montalban-Bravo, Guillermo, Ferrajoli, Alessandra, Jabbour, Elias J., Jain, Nitin, Ohanian, Maro, Takahashi, Koichi, Thompson, Philip A., Loghavi, Sanam, Montalbano, Kathryn S., Pierce, Sherry, Wierda, William G., Kantarjian, Hagop M., Konopleva, Marina Y.
Format:	Artikel
Sprache:	eng
Schlagworte:	631/67/1990/283/1897 692/700/565/1436/2185 Adult Aged Antineoplastic Agents - therapeutic use Biomedical and Life Sciences Biomedicine Bridged Bicyclo Compounds, Heterocyclic - therapeutic use Cancer Research Correspondence Decitabine - therapeutic use Female fms-Like Tyrosine Kinase 3 - antagonists & inhibitors fms-Like Tyrosine Kinase 3 - genetics Hematology Humans Leukemia, Myeloid, Acute - drug therapy Leukemia, Myeloid, Acute - genetics Male Middle Aged Mutation - drug effects Oncology Protein Kinase Inhibitors - therapeutic use Sulfonamides - therapeutic use Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!